Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

By Mark E. Robson, E. Senkus, Binghe Xu, S. Domchek, N. Masuda, S. Delaloge, Nadine Tung, A. Armstrong, Wenting Wu, C. Goessl and 2 more. New England Journal of Medicine, 2017

1,430 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/cb556ddb7bd10a902dcf7fdf573d774a81ac1318

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. K. Polyak
2. N. Turner

In Molecular Biology

1. K. Polyak
2. N. Turner
3. R. Weinberg

In Oncology

1. A. Garrido-Castro
2. K. Polyak
3. R. Weinberg
4. D. Hanahan

Citations in the corpus

• Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer (2019, neutral): “Other platinum‐based treatments 10 (11) 8 (13)”
• Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment (2019, methodology): “, olaparib and talazoparib) have been compared with standard nonplatinum chemotherapy in two phase III trials, OlympiAD and EMBRACA, respectively, in germline BRCA-associated metastatic HER2-negative breast cancer (81, 82).”
• Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. (2020, neutral): “Decreased appetite 80 (31) 4 (2) 24 (18) 1 (<1) 15 (18) 2 (2)”
• ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. (2021, background): “47,48 OS was not improved but a post hoc subset analysis of one study suggested improved OS in patients receiving olaparib who had not received prior ChT for metastatic disease.”